2007
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors
Goel S, Bauer R, Desai K, Bulgaru A, Iqbal T, Strachan B, Kim G, Kaubisch A, Vanhove G, Goldberg G, Mani S. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals Of Oncology 2007, 18: 1704-1707. PMID: 17693421, DOI: 10.1093/annonc/mdm280.Peer-Reviewed Original ResearchConceptsING-1Human anti–human antibody (HAHA) responsesMonoclonal antibodiesGrade 3 pancreatitisAdvanced solid tumorsAdvanced refractory cancerPeak drug levelsRisk of pancreatitisAnti-tumor effectsStable diseaseMonotherapy studiesThird doseAntibody responseRefractory cancerMost adenocarcinomasDrug levelsPharmacokinetic samplesWeek 1Colon cancerPatientsSolid tumorsDrug accumulationCombination studiesFurther experienceSafety studiesPO-50 Management practices of Connecticut physicians for treatment of cancer patients with venous thrombosis
Dhami R, Bulgaru A, Jagathambal K, Johnson S, Kapur D, Slater D, Dhami M. PO-50 Management practices of Connecticut physicians for treatment of cancer patients with venous thrombosis. Thrombosis Research 2007, 120: s161. DOI: 10.1016/s0049-3848(07)70203-7.Peer-Reviewed Original Research
2005
Use of Venipuncture Blood Sample for INR Testing on a Point of Care Machine.
Dhami M, Bulgaru A, Jagathambal K, Kapur D, Norris F, Slater D, Cavanaugh J. Use of Venipuncture Blood Sample for INR Testing on a Point of Care Machine. Blood 2005, 106: 4159. DOI: 10.1182/blood.v106.11.4159.4159.Peer-Reviewed Original ResearchInternational normalized ratioVenipuncture blood sampleINR testingPOC machineBlood samplesWarfarin therapyLong-term oral anticoagulationPOC INR testingSame dayFingerstick blood samplesProcedure of choiceSodium citrate tubesRegression analysisSame blood sampleAdditional laboratory testingOral anticoagulationINR monitoringDose modificationMost patientsAntecubital veinNormalized ratioBlood drawOncology practicePatientsVenipuncture samples
2004
A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies
Friedman D, Goel S, Desai K, Verdier-Pinard D, Kaubisch A, Bulgaru A, Camacho F, Goldberg G, Mani S. A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies. Journal Of Clinical Oncology 2004, 22: 2113-2113. DOI: 10.1200/jco.2004.22.14_suppl.2113.Peer-Reviewed Original ResearchA phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies
Friedman D, Goel S, Desai K, Verdier-Pinard D, Kaubisch A, Bulgaru A, Camacho F, Goldberg G, Mani S. A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies. Journal Of Clinical Oncology 2004, 22: 2113-2113. DOI: 10.1200/jco.2004.22.90140.2113.Peer-Reviewed Original Research
2003
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors
Goel S, Bulgaru A, Hochster H, Wadler S, Zamboni W, Egorin M, Ivy P, Leibes L, Muggia F, Lockwood G, Harvey E, Renshaw G, Mani S. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. Annals Of Oncology 2003, 14: 1682-1687. PMID: 14581279, DOI: 10.1093/annonc/mdg453.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityAdvanced solid tumorsSolid tumorsCycle 1Day 1Cycle 1 dose-limiting toxicitiesDose levelsPhase I clinical studyGrade 3 toxicityPhase II doseGemcitabine combinationNovel regimenPartial responseClinical studiesPatientsGemcitabineOxaliplatinRPTDTitration schemeTumorsDL-4RegimenCycle 2Further investigationDose